For the Inventor, By the Inventor

Enter assignee name

Heidelberg, Germany

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

USPTO Granted Patents = 160

CIPO Patents = 9

EPO Patents = 68

Forward Citations = 1,340

Loading Chart...

Loading Chart...

346 inventors (with patents filed for the assignee):

Harald Zur Hausen (16 out of 27 patents)

Christof Niehrs (11 out of 15 patents)

Wolfgang Maier-Borst (11 out of 15 patents)

4. Ethel-Michele De Villiers-Zur Hausen (9 out of 12 patents)

5. Gerd Stehle (9 out of 14 patents)

6. Hans-Hermann Schrenk (9 out of 12 patents)

7. Frank Breitling (8 out of 12 patents)

8. Melvyn Little (8 out of 23 patents)

9. Jean Rommelaere (7 out of 33 patents)

10. Peter Krammer (7 out of 11 patents)

11. Peter Altevogt (7 out of 8 patents)

12. Manfred Wiessler (7 out of 12 patents)

13. Bisei Okawara (6 out of 6 patents)

14. Olga Kazanskaya (6 out of 9 patents)

15. Wolfgang Schlegel (5 out of 8 patents)

Core Competencies:

Parvovirus H-1 Production

PSMA Binding Antibody

Annexin-Coated Particles

Tumor Therapy

Biomarker for Colorectal Cancer

Pancreatic Cancer Therapy

Oligonucleotide Sequences

Cytotoxic T Cell Response Modifiers

Angiogenesis Modulators

Immunotherapy

Reactive Oxygen Species

Augmented Imaging

160 patents: Sort by Forward Citations

1. 12404498 - Optimized parvovirus H-1 production (2025-09-02),

2. 12398208 - PSMA binding antibody and uses thereof (2025-08-26),

3. 12329800 - Annexin-coated particles (2025-06-17),

4. 12329491 - Method and system for augmented imaging in open treatment using multispectral information (2025-06-17),

5. 12285474 - Vsg-based vaccination and antibody generation platform for the treatment of diseases (2025-04-29),

6. 12282020 - Use of BMMFI Rep protein as biomarker for colorectal cancer (2025-04-21),

7. 12252519 - Crystal structure of a replication protein encoded by a plasmid isolated from a multiple sclerosis patient (2025-03-18),

8. 12195543 - Anti-FLTantigen binding proteins (2025-01-14),

9. 11931349 - Iron chelators in tumor therapy (2024-03-19),

10. 11866495 - Anti-CEACAM6 antibodies and uses thereof (2024-01-09),

11. 11851463 - Core domain of annexins and uses thereof in antigen delivery and vaccination (2023-12-26),

12. 11806361 - Treatments of non-alcoholic steatohepatitis (NASH) (2023-11-07),

13. 11802285 - Cytotoxic T cell response modifiers (2023-10-31),

14. 11773164 - Anti-CEACAM6 antibodies and uses thereof (2023-10-03),

15. 11718662 - Rep protein as protein antigen for use in diagnostic assays (2023-08-08),

The DEUTSCHES KREBSFORSCHUNGSZENTRUM (German Cancer Research Center) is a foundation under public law located in Heidelberg, Germany. It is devoted to researching and understanding the causes of cancer and developing methods for its prevention, diagnosis, and treatment. The center collaborates with national and international partners to promote cancer research and translates scientific findings into medical improvements, aiming to contribute to reducing the impact of cancer on society.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

160 Patents

#2 in Heidelberg

#415 in Germany

#5,015 in the World

Heidelberg, Germany

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Forward Citations = 1,340

346 inventors:

Harald Zur Hausen (16 out of 27 patents)

Christof Niehrs (11 out of 15 patents)

Wolfgang Maier-Borst (11 out of 15 patents)

4. Ethel-Michele De Villiers-Zur Hausen (9 out of 12 patents)

5. Gerd Stehle (9 out of 14 patents)

Please report any incorrect information to support@idiyas.com

Loading…